Dipeptidyl peptidase-4 inhibitors suppress myofibroblastic differentiation and hyaluronan synthesis in Graves' orbitopathy fibroblasts. [PDF]
Shih CW +7 more
europepmc +1 more source
A multidisciplinary approach to the management of Graves' orbitopathy is widely recommended. The optimal model for health care delivery to patients with Graves' orbitopathy is combined thyroid-eye clinics.
Wiersinga, Wilmar M.
core
Development of Graves orbitopathy after thyroidectomy for thyroid cancer. [PDF]
Hormiz M +5 more
europepmc +1 more source
Efficacy and safety of tocilizumab in the treatment of Graves' orbitopathy: a systematic review and meta-analysis. [PDF]
Chen J, Chen Y, Huang H, Duan H.
europepmc +1 more source
Assessment of disease activity in Graves' orbitopathy. [PDF]
Potvin ARGG +5 more
europepmc +1 more source
Unilateral proptosis as the manifestation of euthyroid Graves orbitopathy: A case report. [PDF]
Rauniyar S +4 more
europepmc +1 more source
Complications after radiotherapy in patients with Graves' orbitopathy: A nationwide cohort study. [PDF]
Lee J, Ahn HY, Heo JS, Kim M, Lee JK.
europepmc +1 more source
Selenium Supplementation in Graves' Orbitopathy: Effects on Blood Concentrations and Clinical Outcomes. [PDF]
Lumyongsatien M +5 more
europepmc +1 more source
Dysthyroid Optic Neuropathy in Graves' Orbitopathy: Insights from a Single Centre and Limitations of the Radiological Indices. [PDF]
Agarwal K +12 more
europepmc +1 more source
Unravelling the pathogenic mechanisms in Graves' orbitopathy. [PDF]
Lee ACH, Kahaly GJ.
europepmc +1 more source

